Evidence map›Paper›PMID 39567356›Full record

ArticleHelicobacter

Helicobacter pylori Eradication Therapy and the Risk of Colorectal Cancer: A Population-Based Nationwide Cohort Study in Sweden.

Qing Liu, Omid Sadr-Azodi, Lars Engstrand, Katja Fall, Nele Brusselaers

Abstract read
In one paragraph

Article in Helicobacter. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Sex-Specific Associations ofThe world journal of men's health · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. EClinicalMedicine · 2025
    Article
  8. Effect ofImmunotherapy · 2025
    Review
  9. Beyond the stomach: the association betweenFrontiers in cellular and infection microbiology · 2025
    Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Qing LiuCentre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
Omid Sadr-AzodiDepartment of Clinical Sciences, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
Lars EngstrandCentre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0002-7713-2373
Katja FallClinical Epidemiology and Biostatistics School of Medical Sciences, Örebro University, Örebro, Sweden.
Nele BrusselaersCentre for Translational Microbiome Research, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.ORCID https://orcid.org/0000-0003-0137-447X

Funding

China Scholarship Council 201700260302Vetenskapsrådet 2020-01058
6 · The paper itself

Abstract

backgroundHelicobacter pylori (H. pylori) is an established gastric carcinogen, also associated with an increased risk of colorectal cancer. Therefore, we suspected that H. pylori eradication lowers the risk of colorectal cancer. MATERIAL AND

methodsWe assessed if H. pylori eradication therapy is associated with a reduced risk of colorectal adenocarcinoma in a population-based nationwide cohort study. This study included all Swedish adults with at least one recorded H. pylori eradication episode between July 2005 and December 2012, based on the high-quality Swedish health registries. Colorectal adenocarcinoma risks were compared to the Swedish background population, presented as standardized incidence ratios (SIRs) and 95% confidence intervals (CIs), accounting for age, sex, calendar period, tumor location (left or right sided), stage, and number of eradication episodes, from 1 year after eradication and onward.

resultsAmong 80,381 individuals receiving H. pylori eradication therapy (average follow-up 4.1 years), 282 were diagnosed with colorectal cancer (97.2% adenocarcinoma). Overall, H. pylori eradication was associated with an elevated risk of colorectal adenocarcinoma (SIR 1.27, 95% CI: 1.12-1.43). The colorectal adenocarcinoma risk was increased 1-2 years after eradication (SIR 1.42, 95% CI: 1.17-1.72), then decreased 2-4 years (SIR 0.80, 95% CI: 0.65-0.98) and 4-6 years (SIR 0.76, 95% CI: 0.57-0.99), yet not ≥ 6 years (SIR 1.36, 95% CI: 0.78-2.21) after eradication compared to the general population. Overall, right-sided (SIR 1.47, 95% CI: 1.21-1.76) and left-sided (SIR 1.35, 95% CI: 1.09-1.67) colon adenocarcinomas risks were higher among eradicated individuals than the general population.

conclusionH. pylori eradication was not associated with a clear and consistent reduction of colorectal cancer in our Swedish cohort.

Indexed as

Colorectal NeoplasmsHelicobacter InfectionsHelicobacter pyloriAdenocarcinomaAdolescentAdultAgedAged, 80 and overAnti-Bacterial AgentsCohort StudiesFemaleHumansIncidenceMaleMiddle AgedSwedenAnti-Bacterial Agentsantibioticscancer riskcolorectal adenocarcinomaHelicobacter pylori eradication therapyproton pump inhibitors

Identifiers

PMID39567356
PMCPMC11578941

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.